Serum S100B protein after electroconvulsive therapy in patients with depression
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Serum S100B protein after electroconvulsive therapy in patients with depression. / Gbyl, Krzysztof; Jørgensen, Niklas Rye; Videbech, Poul.
I: Acta Neuropsychiatrica, Bind 34, Nr. 5, 2022, s. 269–275.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Serum S100B protein after electroconvulsive therapy in patients with depression
AU - Gbyl, Krzysztof
AU - Jørgensen, Niklas Rye
AU - Videbech, Poul
N1 - Publisher Copyright: © Scandinavian College of Neuropsychopharmacology 2022.
PY - 2022
Y1 - 2022
N2 - Objective: S100B is a glial cell protein with bimodal function. In low concentrations, it exerts neurotrophic effects, but higher levels reflect neuronal distress. Recent research suggests that this molecule may be a biomarker of response to electroconvulsive therapy (ECT). We examined the effect of ECT on serum S100B and its utility as 1) a biomarker of a depressive state and 2) a predictor of ECT response. We also wanted to ensure that ECT does not cause a marked serum S100B-elevation, indicating neural distress. Methods: We measured serum S100B in 22 in-patients treated with ECT due to depression. Depression severity was assessed using 17-item Hamilton Rating Scale for Depression (HAMD-17). The data were collected before an ECT series, within one week after the series (post-ECT), and at a six-month follow-up. Changes in serum S100B and clinical outcomes were tested using a linear mixed model. A relationship between serum S100B and the clinical outcomes was examined using Spearman and partial correlation. Results: Serum S100B did not change significantly immediately after an ECT series or six months later. The post-ECT serum S100B-change was not associated with the clinical effect (rho=.14, n=22, p=.54). The baseline serum S100B did not predict the clinical effect when controlling for age (r =.02, n=22, df=19, p=.92). Conclusion: The study neither supports serum S100B as a state marker of depression nor a predictor of ECT response. No evidence for ECT-related neural distress was found.
AB - Objective: S100B is a glial cell protein with bimodal function. In low concentrations, it exerts neurotrophic effects, but higher levels reflect neuronal distress. Recent research suggests that this molecule may be a biomarker of response to electroconvulsive therapy (ECT). We examined the effect of ECT on serum S100B and its utility as 1) a biomarker of a depressive state and 2) a predictor of ECT response. We also wanted to ensure that ECT does not cause a marked serum S100B-elevation, indicating neural distress. Methods: We measured serum S100B in 22 in-patients treated with ECT due to depression. Depression severity was assessed using 17-item Hamilton Rating Scale for Depression (HAMD-17). The data were collected before an ECT series, within one week after the series (post-ECT), and at a six-month follow-up. Changes in serum S100B and clinical outcomes were tested using a linear mixed model. A relationship between serum S100B and the clinical outcomes was examined using Spearman and partial correlation. Results: Serum S100B did not change significantly immediately after an ECT series or six months later. The post-ECT serum S100B-change was not associated with the clinical effect (rho=.14, n=22, p=.54). The baseline serum S100B did not predict the clinical effect when controlling for age (r =.02, n=22, df=19, p=.92). Conclusion: The study neither supports serum S100B as a state marker of depression nor a predictor of ECT response. No evidence for ECT-related neural distress was found.
KW - depression
KW - depressive disorder
KW - Electroconvulsive therapy
KW - mood disorders
KW - S100 calcium-binding protein beta subunit
U2 - 10.1017/neu.2022.8
DO - 10.1017/neu.2022.8
M3 - Journal article
C2 - 35249591
AN - SCOPUS:85126808571
VL - 34
SP - 269
EP - 275
JO - Acta Neuropsychiatrica
JF - Acta Neuropsychiatrica
SN - 0924-2708
IS - 5
ER -
ID: 312701744